ANAPTYSBIO, INC — Director's Dealing 2017

Jan 26, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-25

Reporting Person: Novo A/S (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (1428571)		Direct
Series C Preferred Stock	$		Common Stock (486820)		Direct
Series C-1 Preferred Stock	$		Common Stock (312986)		Direct
Series D Preferred Stock	$		Common Stock (673454)		Direct
Series C Preferred Stock Warrant (Right to Buy)	$4.55	2018-11-04	Common Stock (117235)		Direct

Footnotes

F1: The Series B Preferred Stock. Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Immediately prior to the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock will automatically convert on a one-for-one basis for no additional consideration into common stock. The number of shares reported on this line item reflects the approximate number of shares of common stock subsequent to the 7-for-1 reverse split of common stock effected by the Issuer on January 13, 2017.

F2: Immediately prior to the IPO Closing, the warrant will become exercisable for shares of common stock.